Acumen is developing targeted therapies for safe and effective treatment of Alzheimer’s disease (AD) and related neurodegenerative diseases. Its lead candidate, ACU193 is a fully humanized IgG2m4 monoclonal antibody which selectively binds amyloid beta Aβ oligomers (Aβo) – now recognized as the most toxic form of amyloid in AD.
ACU193 is an exceptionally well-characterized antibody drug candidate and is the result of an eight-year collaboration between Acumen and Merck & Co. Acumen has exclusive rights to the program.
ACU193 has the potential as first- and/or best-in-class as monotherapy, with a lower or no rate of ARIA-E and a greater clinical benefit for patients. In addition, ACU193 could also be a synergistic combination drug to several of the emerging anti-tau, anti-inflammatory or anti-infectious agents in the pipeline as this disease is unlikely to get treated effectively with a single agent.